

Special Issue

State-of-the Art on Cervical Cancer

Message from the Guest Editors

Treatment of cervical cancer still represents a challenge particularly when it is diagnosed in the locally advanced stage. It is the fourth most common cancer among women. In recent decades many advances were carried on prevention by vaccination of HPV and screening of pre-invasive disease. However, all preventive strategies will be effective only in the distant future, 20 to 30 years from now. In this Special Issue, an international team of experts will try to discuss and address a comprehensive scenario on the state-of-the-art of this disease. Topics ranging from a epidemiology and demography of cervical cancer, to clinical reviews and original papers on diagnosis and prevention programs, the role of surgery, particularly regarding the sentinel node mapping and lymphadenectomy, modulation of radical hysterectomy, the fertility sparing approaches, the role of radiotherapy and combined modality treatment are all welcome.

Guest Editors

Dr. Alessandro Antonio Buda


Division of Gynecologic Oncology, Michele e Pietro Ferrero Hospital, Verduno, Italy

Dr. Francesco Fanfani

Department of Life Sciences and Public Health, Gemelli Polyclinic Hospital, Rome, Italy

Deadline for manuscript submissions

closed (15 July 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/154807

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).